Business
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.Collaboration leverages Neomorph's
About this update from Biogen Inc.
[{"type":"text","content":"The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer’s, rare, and immunological diseases. CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of the collaboration, the companies aim to utilize Neomorph's proprietary molecular glue discovery platform to accelerate the identification and validation of novel small molecule therapeutic molecular glue degraders. Small molecule protein degraders have been shown to effectively drug challenging targets with differentiated pharmacology from more traditional inhibitors. Pursuing innovative solutions aimed at modulating protein levels through targeted degradation holds promise for treating complex neurological, immunological and rare diseases. This collaboration will leverage Neomorph’s research strengths in targeted protein degradation and Biogen’s deep scientific expertise and drug development capabilities. \"As part of our modality agnostic research strategy, Biogen is committed to investing in new approaches to unlock biological targets that have remained difficult to reach,\" said Jane Grogan, Ph.D., Head of Research at Biogen. \"This collaboration with Neomorph reflects the approach we want to take to pair our internal drug development expertise with cutting-edge external innovation to create clinically meaningful therapies for patients.\" \"Neomorph's molecular glue degrader platform represents a unique approach to drug discovery,\" said Phil Chamberlain, DPhil, Co-Founder, President, and Chief Executive Officer of Neomorph. \"We are excited to partner with Biogen, a leader in Alzheimer’s, rare, and immunological diseases, to explore the potential of our technology in addressing some of the most challenging and valuable targets in these fields.\" Under the terms of the agreement, Biogen and Neomorph will collaborate to identify, validate, and optimize small molecule molecular glue degraders for several high-priority targets and Biogen will advance clinical cand...